Drug intelligence / Profile preview

IBI356

Development stage: Phase 2
Lead developer: Suzhou Innovent Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

IBI356 is a monoclonal antibody drug candidate developed by Innovent Biologics. It targets the OX40 ligand (also known as TNF Superfamily Member 4), acting as an antagonist to modulate immune responses. The drug is being investigated primarily for its anti-inflammatory effects, with its main mechanism of action involving inhibition of the OX40 ligand pathway. As of early 2024, IBI356 is in phase 1 clinical trials for atopic dermatitis and has also been studied preclinically for other autoimmune disorders.

Targets

TNFSF4 (Tumor necrosis factor ligand superfamily member 4)

Beyond the preview

Go deeper on IBI356.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBI356.

Explore the full profile